Angiotensin receptors are a class of G protein-coupled receptors with angiotensin II as their ligands. They are important in the renin-angiotensin system: they are responsible for the signal transduction of the vasoconstricting stimulus of the main effector hormone, angiotensin II. The AT1 and AT2 receptors have a similar affinity for angiotensin II, which is their main ligand. The AT1 receptor is the best elucidated angiotensin receptor. AT2 receptors are more plentiful in the fetus and neonate. Other poorly characterized subtypes include the AT3 and AT4 receptors.
Angiotensin Receptor Inhibitors & Modulators

A 779
(Asp-Arg-Tyr-Ile-His-d-Ala; DRVYI(d-ALA))
Cat. No.: HY-P0216

Bioactivity: A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor), which is an Ang1-7 receptor distinct from the classical AngII.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg

A81988
(Abbott81988)
Cat. No.: HY-U00188

Bioactivity: A81988 is a potent, competitive, non-peptidic antagonist of angiotensin AT₁ receptors.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Angiotensin 1-7
(Angiotensin-(1-7), Ang-(1-7))
Cat. No.: HY-12403

Bioactivity: Angiotensin 1-7 inhibits purified canine angiotensin converting enzyme (ACE) activity with an IC₅₀ of 0.65 μM.

Purity: 99.61%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg

Angiotensin II (3-8), human
Cat. No.: HY-P1515

Bioactivity: Angiotensin II (3-8), human is a less effective agonist at the angiotensin AT₁ receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Angiotensin II 5-valine
(Valine angiotensin II, 5-L-Valine angiotensin II)
Cat. No.: HY-P0108

Bioactivity: Angiotensin II 5-valine is an angiotensin II analog which is an agonist at angiotensin receptors

Purity: 95.90%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg

Angiotensin III, human, mouse
Cat. No.: HY-P1540

Bioactivity: Angiotensin III, human, mouse is a heptapeptide, acts as an endogenous angiotensin type 2 receptor (AT₂R) agonist, with IC₅₀ s of 0.648 nM and 21.1 nM for AT₂R and AT₁R, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size:

AVE 0991
Cat. No.: HY-15778

Bioactivity: AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) agonist. AVE 0991 competes for high-affinity binding of [¹²⁵I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC₅₀ of 21±35 nM.

Purity: 99.16%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

AVE 0991 sodium salt
Cat. No.: HY-15778A

Bioactivity: AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) agonist. AVE 0991 competes for high-affinity binding of [¹²⁵I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC₅₀ of 21±35 nM.

Purity: 99.32%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Azilsartan
(TAK-536)
Cat. No.: HY-14914

Bioactivity: Azilsartan(TAK-536) is a specific and potent angiotensin II type 1 receptor antagonist with IC₅₀ of 2.6 nM.

Purity: 99.58%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg
| **Azilsartan D5**  
TAK-536 D5 | **Azilsartan medoxomil**  
TAK-491 | **Azilsartan medoxomil monopotassium**  
Azilsartan kamedoxomil; TAK 491 monopotassium | **BIBS 39**  
Cat. No.: HY-19732 | **C-Type Natriuretic Peptide (CNP) (1-22), human**  
Cat. No.: HY-P1237 | **Candesartan**  
CV 11974 | **Candesartan Cilexetil**  
TCV-116 | **Candesartan D4**  
CV-11974 D4 | **CGP-42112**  
(CGPG42112A) | **CGP48369**  
Cat. No.: HY-12405 | **CGP48369**  
Cat. No.: HY-101706 |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Azilsartan D5 is the deuterium labeled Azilsartan(TAK-536), which is a specific and potent angiotensin II type 1 receptor antagonist.</td>
<td><strong>Bioactivity:</strong> Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.</td>
<td><strong>Bioactivity:</strong> Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.</td>
<td><strong>Bioactivity:</strong> BIBS 39 is a new nonpeptide angiotensin II (All) receptor antagonist.</td>
<td><strong>Bioactivity:</strong> C-Type Natriuretic Peptide (CNP) (1-22), human is the 1-22 fragment of C-Type Natriuretic Peptide. C-type natriuretic peptide is natriuretic peptide family peptide that is involved in the maintenance of electrolyte-fluid balance and vascular tone.</td>
<td><strong>Bioactivity:</strong> Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.</td>
<td><strong>Bioactivity:</strong> Candesartan is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.</td>
<td><strong>Bioactivity:</strong> Candesartan D4 is the deuterium labeled Candesartan, which is an angiotensin II receptor antagonist.</td>
<td><strong>Bioactivity:</strong> CGP-42112(CGPG42112A) is a potent Angiotensin-II subtype 2 receptor(AT2 R) agonist</td>
<td><strong>Bioactivity:</strong> CGP48369 is a nonpeptidic angiotensin II receptor antagonist, used for anti-hypertensive research.</td>
<td><strong>Bioactivity:</strong> CGP48369 is a nonpeptidic angiotensin II receptor antagonist, used for anti-hypertensive research.</td>
<td></td>
</tr>
<tr>
<td>Purity: 98.0%</td>
<td>Purity: &gt;98%</td>
<td>Purity: 95.35%</td>
<td>Purity: 99.36%</td>
<td>Purity: &gt;98%</td>
<td>Purity: 96.20%</td>
<td>Purity: 98.0%</td>
<td>Purity: &gt;98%</td>
<td>Purity: 98.82%</td>
<td>Purity: &gt;98%</td>
<td>Purity: &gt;98%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 1 mg, 5 mg, 10 mg</td>
<td><strong>Size:</strong> 5 mg, 10 mg, 50 mg</td>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg</td>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 10 mg, 50 mg</td>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 10 mg, 50 mg</td>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</td>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg</td>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg</td>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg</td>
<td></td>
</tr>
</tbody>
</table>

Azilsartan medoxomil monopotassium (Azilsartan kamedoxomil; TAK 491 monopotassium) is also available as a monopotassium salt, with Cat. No. HY-17458.

BIBS 39 is available in multiple forms, with Cat. No. HY-19732.

C-Type Natriuretic Peptide (CNP) (1-22), human is available with Cat. No. HY-P1237.

Candesartan is available with Cat. No. HY-8205.

Candesartan Cilexetil (TCV-116) is available with Cat. No. HY-17505.

Candesartan D4 is available with Cat. No. HY-82055.

CGP-42112 (CGP42112A) is available with Cat. No. HY-12405.

CGP48369 is available with Cat. No. HY-101706.
<table>
<thead>
<tr>
<th>Substance</th>
<th>Cat. No.</th>
<th>Bioactivity</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elisartan (HN 65021)</td>
<td>HY-19214</td>
<td>Elisartan is an orally active non-peptide pro-drug of angiotensin II AT1 receptor antagonist HN-12206, and shows anti-hypertension activities.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td>EMA401 (Olodanrigan)</td>
<td>HY-13106</td>
<td>EMA401, a highly selective AT2R antagonist, inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons</td>
<td>98.52%</td>
<td>Phase 2</td>
<td>10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg</td>
</tr>
<tr>
<td>Eprosartan mesylate</td>
<td>HY-15834A</td>
<td>Eprosartan is a nonpeptide angiotensin II receptor antagonist with IC50 of 9.2 and 3.9 nM in rat and human adrenal cortical membranes, respectively.</td>
<td>99.79%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Fimasartan (BR-A-657)</td>
<td>HY-80780</td>
<td>Fimasartan(BR-A-657) is a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension and heart failure.</td>
<td>98.77%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Irbesartan (SR-47436; BMS-186295)</td>
<td>HY-80202</td>
<td>Irbesartan is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.</td>
<td>99.79%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Irbesartan D4 (SR-47436 D4; BMS-186295 D4)</td>
<td>HY-80202S</td>
<td>Irbesartan D4 is the deuterium labeled Irbesartan, which is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td>L-159282 (MK 996)</td>
<td>HY-19191</td>
<td>L-159282 is a highly potent, orally active, nonpeptide angiotensin II receptor antagonist, with anti-hypertensive activity.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td>L162389</td>
<td>HY-101618</td>
<td>L162389 is a potent antagonist of angiotensin AT1 receptor with $K_i$ of 28 nM.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td>L162441</td>
<td>HY-U00245</td>
<td>L162441 is an Angiotensin type 1 receptor antagonist.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td>LCZ696 (Valsartan/sacubitril)</td>
<td>HY-18204A</td>
<td>LCZ696 is a dual angiotensin II receptor and neprilysin inhibitor.</td>
<td>99.96%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</td>
</tr>
<tr>
<td>Compound</td>
<td>Cat. No.</td>
<td>Bioactivity</td>
<td>Purity</td>
<td>Clinical Data</td>
<td>Size</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>---------</td>
<td>------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Losartan (DuP-753)</td>
<td>HY-17512</td>
<td>Losartan is an <strong>angiotensin II receptor</strong> antagonist, competing with the binding of angiotensin II to AT1 receptors with <strong>IC_{50}</strong> of 20 nM.</td>
<td>99.24%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 1 g, 5 g</td>
</tr>
<tr>
<td>Losartan D4 (DuP-753 D4)</td>
<td>HY-17512S</td>
<td>Losartan D4 is the deuterium labeled Losartan. Losartan is an <strong>angiotensin II receptor</strong> antagonist, competing with the binding of angiotensin II to AT1 receptors with <strong>IC_{50}</strong> of 20 nM.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td>Losartan D4 Carboxylic Acid (E-3174 D4, EXP-3174 D4)</td>
<td>HY-12765S</td>
<td>Losartan D4 Carboxylic Acid is the deuterium labeled Losartan(EXP-3174), which is an angiotensin II receptor antagonist.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg</td>
</tr>
<tr>
<td>Losartan potassium (DuP-753 potassium)</td>
<td>HY-17512A</td>
<td>Losartan (potassium) is an <strong>angiotensin II receptor</strong> antagonist, competing with the binding of angiotensin II to AT1 receptors with <strong>IC_{50}</strong> of 20 nM.</td>
<td>99.91%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 1 g, 5 g</td>
</tr>
<tr>
<td>LY285434</td>
<td>HY-U00202</td>
<td>LY285434 is a suitable <strong>angiotensin II receptor</strong> antagonist.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td>Olmesartan (RNH 6270; CS 088)</td>
<td>HY-17004</td>
<td>Olmesartan is an <strong>angiotensin II receptor (AT1R)</strong> antagonist used to treat high blood pressure.</td>
<td>99.01%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 100 mg, 500 mg</td>
</tr>
<tr>
<td>Olmesartan D4 (RNH-6270 D4, CS-088 D4)</td>
<td>HY-170045</td>
<td>Olmesartan D4 is the deuterium labeled Olmesartan. Olmesartan is an <strong>angiotensin II receptor (AT1R)</strong> antagonist used to treat high blood pressure.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td>Olmesartan medoxomil (CS 866)</td>
<td>HY-17005</td>
<td>Olmesartan medoxomil is a potent and selective <strong>angiotensin AT1 receptor inhibitor</strong> with <strong>IC_{50}</strong> of 66.2 μM.</td>
<td>99.03%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>PD 123319 (S)-(+)-PD 123319</td>
<td>HY-10259</td>
<td>PD 123319 (detrifluoroacetate) is a potent, selective <strong>AT2 angiotensin II receptor</strong> antagonist with <strong>IC_{50}</strong> of 34 nM.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>5 mg, 10 mg, 50 mg</td>
</tr>
<tr>
<td>PD 123319 ditrifluoroacetate</td>
<td>HY-10259A</td>
<td>PD 123319 (detrifluoroacetate) is a potent, selective <strong>AT2 angiotensin II receptor</strong> antagonist with <strong>IC_{50}</strong> of 34 nM.</td>
<td>99.76%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in Water, 5 mg, 10 mg, 50 mg</td>
</tr>
</tbody>
</table>
Pratosartan  
(FW 7203; KD 3-671; KT 3671)  
Cat. No.: HY-101574

Bioactivity: Pratosartan is a selective angiotensin II receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

SL910102

Cat. No.: HY-100292

Bioactivity: SL910102 is a nonpeptide angiotensin AT1 receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Sparsentan  
(REE-021; BMS-346567; PS433540; DARA-a)  
Cat. No.: HY-17621

Bioactivity: Sparsentan (REE-021; BMS-346567; PS433540; DARA-a) is a highly potent dual angiotensin II and endothelin A receptor antagonist with \( K_i \) of 0.8 and 9.3 nM, respectively.

Purity: 99.08%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tasosartan  
(WAY-ANA 756)  
Cat. No.: HY-A0250

Bioactivity: Tasosartan is a long-acting angiotensin II (AngII) receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Telmisartan  
(BIBR 277)  
Cat. No.: HY-13955

Bioactivity: Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of \( ^{125} \)I-AngII to AT1 receptors with \( IC_{50} \) of 9.2 nM.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg, 1 g

Trans-Tranilast  
(trans-Tranilast)  
Cat. No.: HY-18706

Bioactivity: Trans-Tranilast is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis.

Purity: 99.66%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg

Telmisartan  
(BIBR 277)  
Cat. No.: HY-13955

Bioactivity: Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of \( ^{125} \)I-AngII to AT1 receptors with \( IC_{50} \) of 9.2 nM.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg, 1 g

Tranilast  
(MK 341; SB 252218)  
Cat. No.: HY-B0195

Bioactivity: Tranilast is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of \( ^{125} \)I-AngII to AT1 receptors with \( IC_{50} \) of 9.2 nM.

Purity: 99.60%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg

Tranilast Sodium  
(Sodium Tranilast; MK 341 Sodium; SB 252218 Sodium)  
Cat. No.: HY-B0195A

Bioactivity: Tranilast is an antiallergic agent

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg

Valsartan  
(CGPG 48933)  
Cat. No.: HY-18204

Bioactivity: Valsartan (CGP-48933) is an angiotensin II receptor antagonist for treatment of high blood pressure and heart failure.

Purity: 99.35%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

Valsartan D9  
(CGPG-48933 D9)  
Cat. No.: HY-18204S

Bioactivity: Valsartan D9 (CGP-48933 D9) is deuterium labeled valsartan. Valsartan is an angiotensin II receptor antagonist for treatment of high blood pressure and heart failure.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg
| Bioactivity: [Sar1, Ile8]-Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels. |
|---|---|
| Purity: | > 98% |
| Clinical Data: | No Development Reported |
| Size: | Cat. No.: HY-P1564 |